Company intelligence / Profile preview

Gliomic Therapeutics

Tel Aviv, Israel

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Gliomic is developing an AI-driven liquid biopsy platform for the non-invasive detection and monitoring of glioblastoma and other brain tumors. Their technology utilizes machine learning to analyze cell-free DNA (cfDNA) methylation patterns in blood samples, providing molecular profiling that traditionally required invasive neurosurgical biopsies.

Therapeutic areas: Oncology
Modalities: Liquid biopsyAI-based diagnostics
Industry: Molecular Diagnostics

Partnerships

Sanara VenturesTeva Pharmaceutical IndustriesRoyal Philips

Beyond the preview

Go deeper on Gliomic Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gliomic Therapeutics.

Explore the full profile